Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs
Nucleic Acid Therapeutics · 01.06.2025 · 35 (3) · 137-149
DOI: 10.1089/nat.2024.0077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.06.2025. Verfasst von Daniel O'Reilly und 6 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: RNA, Small Interfering, Ribose. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Chemically modified short interfering RNAs (siRNAs) unequivocally represent a groundbreaking class of drugs. The deliberate chemical modification of the natural structure has been pivotal to their resounding success. Specific modifications at certain positions bolster their potency, safety, stability, and specificity. In clinical research, 2′- O -methyl and 2′-fluoro are the most used modifications. The effects of a wide range of chemical changes in fully modified siRNAs have not been thoroughly evaluated for tolerability. In this study, we utilized two sequences in a fully modified siRNA to systematically assess the tolerability of single nucleotide backbone and sugar modifications, including deoxyribonucleic acid, 2′- O -(2-methoxyethyl), locked nucleic acid, unlocked nucleic acid, mismatches, butane diol substitution, and butane diol insertion. We synthesized 522 siRNA variants and evaluated their efficacy in vitro . Our findings demonstrate that individual tolerability is significantly influenced by the modification’s sequence, pattern, and position, with limited universal principles identifiable from this dataset. The efficacy results are probably driven by the thermodynamic balance defined by a combination of parameters. The framework presented here will serve as a reference dataset to facilitate the expansion of chemical diversity in therapeutic siRNAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Förderung
- NIGMS NIH HHS
- NIH HHS
Zitieren
APA
O'Reilly, D., Furgal, R., Hariharan, V., Lochmann, C., Cooper, D., Echeverria, D., & Khvorova, A. (2025). Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs. Nucleic Acid Therapeutics, 35(3), 137-149. https://doi.org/10.1089/nat.2024.0077
Vancouver
O'Reilly D, Furgal R, Hariharan V, Lochmann C, Cooper D, Echeverria D, et al. Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs. Nucleic Acid Therapeutics. 2025;35(3):137-149. doi:10.1089/nat.2024.0077
BibTeX
@article{OReilly2025,
author = {O'Reilly, Daniel and Furgal, Raymond and Hariharan, Vignesh and Lochmann, Clemens and Cooper, David and Echeverria, Dimas and Khvorova, Anastasia},
title = {Systematic Evaluation of Position-Specific Tolerability of Seven Backbone and Ribose Modifications in Fully Chemically Stabilized siRNAs},
journal = {Nucleic Acid Therapeutics},
year = {2025},
volume = {35},
number = {3},
pages = {137--149},
doi = {10.1089/nat.2024.0077}
}
EUVIMED